Corcept’s innovative cancer treatment has shown promising results in specific ovarian cancer patients who have developed resistance to conventional chemotherapy.
Corcept Therapeutics recently announced that their anticancer drug, Relacorilant, significantly delayed the progression of platinum-resistant ovarian cancer in late-stage clinical trials.
The study involved 381 ovarian cancer patients and revealed that the combination therapy of Relacorilant and chemotherapy reduced the risk of cancer progression by 30% compared to chemotherapy alone. This groundbreaking treatment extended the average survival by 4.5 months, bringing the total to 16 months.
Relacorilant, an oral medication, works by inhibiting cortisol, a stress hormone known to build resistance against chemotherapy treatments such as platinum therapy.
Currently, treatment options for platinum-resistant ovarian cancer are limited, with AbbVie’s Elahere and Roche’s Avastin being the primary choices.
According to the National Cancer Institute, approximately 200,000 women are diagnosed with ovarian cancer in the U.S. annually, with 20,000 of these cases classified as platinum-resistant.
Most Commented